Enhanced in Vivo Targeting of Murine ... - ACS Publications

Jun 5, 2014 - Children's Hospital, University Medical Center, Johannes Gutenberg ... Department of Medicine, Rhode Island Hospital and the Warren Alpe...
0 downloads 0 Views 6MB Size
Article pubs.acs.org/Biomac

Enhanced in Vivo Targeting of Murine Nonparenchymal Liver Cells with Monophosphoryl Lipid A Functionalized Microcapsules Anette Pietrzak-Nguyen,† Michael Fichter,† Marvin Dedters,† Leah Pretsch,† Stephen H. Gregory,§ Claudius Meyer,† Aysefa Doganci,† Mustafa Diken,∥ Katharina Landfester,‡ Grit Baier,‡ and Stephan Gehring*,† †

Children’s Hospital, University Medical Center, Johannes Gutenberg University, Mainz 55131, Germany Max-Planck Institute for Polymer Research, Mainz 55128, Germany § Department of Medicine, Rhode Island Hospital and the Warren Alpert Medical School at Brown University, Providence, Rhode Island 02903, United States ∥ In Vivo Imaging Core Facility, TRON - Translational Oncology, University Medical Center, Johannes Gutenberg University, Mainz 55131, Germany ‡

S Supporting Information *

ABSTRACT: A broad spectrum of infectious liver diseases emphasizes the need of microparticles for targeted delivery of immunomodulatory substances to the liver. Microcapsules (MCs) are particularly attractive for innovative drug and vaccine formulations, enabling the combination of antigen, drugs, and adjuvants. The present study aimed to develop microcapsules characterized by an enhanced liver deposition and accelerated uptake by nonparenchymal liver cells (NPCs). Initially, two formulations of biodegradable microcapsules were synthesized from either hydroxyethyl starch (HES) or mannose. Notably, HES-MCs accumulated primarily in the liver, while mannose particles displayed a lung preference. Functionalization of HES-MCs with anti-CD40, anti-DEC205, and/or monophosphoryl lipid A (MPLA) enhanced uptake of MCs by nonparenchymal liver cells in vitro. In contrast, only MPLA-coated HES-MCs promoted significantly the in vivo uptake by NPCs. Finally, HES-MCs equipped with MPLA, antiCD40, and anti-DEC205 induced the secretion of TNF-α, IL-6 by Kupffer cells (KCs), and IFN-γ and IL-12p70 by liver dendritic cells (DCs). The enhanced uptake and activation of KCs by MPLA-HES-MCs is a promising approach to prevent or treat infection, since KCs are exploited as an entry gate in various infectious diseases, such as malaria. In parallel, loading and activating liver DCs, usually prone to tolerance, bears the potential to induce antigen specific, intrahepatic immune responses necessary to prevent and treat infections affecting the liver. different approaches including (a) size and shape of particles,9 (b) surface engineering, and (c) receptor-based approaches.10 Size- and shape-based targeting is triggered by the observation that phagocytic capabilities of cells differ between cell populations. A compelling example is the observation that large particles (200 nm to 1 μm) are preferentially cleared from the bloodstream by Kupffer cells (KC) in the liver, whereas small nanoparticles (20−200 nm) are ingested by liver endothelial cells.11 Surface engineered microcarriers offer the opportunity to exploit shell compounds to target cell surface molecules involved in receptor-mediated uptake. Biomaterials used for enhanced uptake include mannose, targeting the mannose receptor (CD206),12 human serum albumin, specific for folate receptor beta (FR-β) positive macrophages,13 and folic acid, also enhancing uptake by FR-β positive macrophages.14 Receptor-mediated targeting is achieved by immobi-

1. INTRODUCTION Targeted delivery of bioactive compounds within the living organism and minimizing toxic side effects drives the growing interest in the development of colloidal microcarriers.1,2 Synthesis of microcarriers made of natural biomolecules (e.g., starch, gelatin, chitosan) has been successfully performed using different preparation methods (e.g., nanoprecipitation, emulsion−diffusion, double emulsification) and polymerization techniques (polyaddition reaction, radical polymerization).3 Due to their potential in diagnostics, imaging, and targeted therapy, colloidal microcarriers, especially liposomes,4 polymeric particles and capsules,5 micelles,6 and dendrimers7 have recently gained great attention. Of high interest are microcarriers that are able to transport bioactive compounds within the human body and release them without causing any toxic effects. Especially encapsulation in polymeric microcapsules has an advantage providing protection for sensitive biomolecules.8 Furthermore, microcapsules can be functionalized for targeting to specific organs, tissues, and cells. This can be achieved by © 2014 American Chemical Society

Received: January 2, 2014 Published: June 5, 2014 2378

dx.doi.org/10.1021/bm5006728 | Biomacromolecules 2014, 15, 2378−2388

Biomacromolecules

Article

and 100 mg of TDI was added dropwise over 5 min to the earlier prepared mixture I at 25 °C. The reaction was performed for 1 day at 25 °C under stirring. After synthesis, MCs were purified by repetitive centrifugation (Sigma 3k-30, RCF 1467, 20 min, two times) and redispersed in cyclohexane. Afterward, the MCs were transferred into the aqueous phase using the following procedure: 1 g of the MCs dispersion in cyclohexane (polymer solid content 3 wt %) was mixed with 5 g of SDS/Ampuwa aqueous solution (0.1 wt %) and kept under mechanical stirring conditions for 1 day at 25 °C. Thereafter, the samples were redispersed in a sonication bath. After redispersion, MCs were dialyzed (MWCO: 12 000 g·mol−1) to remove residues of SDS. 2.1.2.1. Carboxymethylation of Microcapsules. The carboxymethylation of HES-MCs was performed using a modified procedure published previously.27 Briefly, 1.0 g of HES-MCs aqueous dispersion (solid content 1.0 wt %) was mixed with 0.1 mL of NaOH solution (0.1 M) and stirred at 25 °C for 1 day to neutralize the nonreacted hydroxyl groups from the starch molecules on the MC surface. For the carboxymethylation, 10 μL of MCA (20.0 wt %) was mixed with the HES-MCs dispersion (after NaOH addition) and stirred for 1 day at 40 °C. After that, 0.05 mL of a NaOH solution (1.0 M) was added and stirred again for 1 day at 25 °C. Finally, the microcapsule dispersion was centrifuged (20 min, Sigma 3k-30, RCF 1467), the supernatant was removed, and the MCs were redispersed in Ampuwa. The amount of carboxylic groups was determined by polyelectrolyte titration as described below. 2.1.2.2. Coupling of Anti-DEC205, Anti-CD40, or IgG onto HES Microcapsules. A volume of 200 μL of the carboxymethylated HESMC dispersion (solid content 1.0 wt %, 1.88 × 1014 COOH-groups as determined by particle charge determination (PCD)) was mixed with 20 mg (0.13 mmol) of EDC and 20 mg (0.07 mmol) of STP. After stirring for 30 min, the MCs were centrifuged at 4000 rpm for 30 min (Sigma 3k-30, RCF 1467) to remove residuals of EDC and STP. The supernatant was removed, and the pellet was resuspended in Ampuwa. Then 200 μL of DEC205, CD40, or IgG (8.02 × 1014 molecules) was added, and the mixture was stirred for 1 day at 4 °C. After the coupling procedure, the MCs were centrifuged at 4000 rpm for 20 min, the supernatant was removed, and the pellet was redispersed in Ampuwa to remove residues of nonreacted antibodies. 2.1.2.3. Adsorption of MPLA onto Microcapsule Surface. A volume of 250 μL of microcapsule dispersion (solid content 1.0 wt %) was mixed with 60 μL of MPLA/DMSO solution (0.1%) and stirred over 1 day at 4 °C. Afterward, MCs were centrifuged two times at 4000 rpm for 30 min (Sigma 3k-30, RCF 1467) to remove residues of MPLA. Finally, the supernatant was removed and the pellet was redispersed in 0.9% NaCl. 2.1.3. Microcapsule Characterization. Average size, size distribution, and colloidal stability of MCs were analyzed by means of dynamic light scattering (DLS) at 25 °C using a Nicomp 380 submicrometer particle sizer (Nicomp Particle Sizing Systems) at 20 °C. The zeta potential (ζ) of MCs was measured in 10−3 M potassium chloride solution with a Nicomp zeta sizer (Nicomp Particle Sizing Systems) at 20 °C. The amount of surface charged groups was calculated from the results of the titration experiments performed on a particle charge detector (Mütek GmbH, Germany) in combination with a Titrino Automatic Titrator (Metrohm AG, Switzerland). The carboxylic groups were titrated against the positively charged polycationpoly(diallyl dimethylammonium chloride) (poly-DADMAC). The amount of groups per gram of polymer was calculated from the consumed volume of the polyelectrolyte solution.28 Morphological studies were performed using scanning electron microscopy (SEM). For the determination of the antibody coupling efficiency, the absorption at 280 nm was measured. The chemical stability of microcapsules was studied in Ampuwa, 0.9% NaCl, and DPBS buffer. The release of SR101 from MCs was studied by fluorescence spectroscopy in the supernatant: 500 μL of MCs was mixed with 500 μL of Ampuwa, 0.9% NaCl, or DPBS, incubated at 37 °C for 24 h, and then centrifuged (Sigma 3k-30, RCF 1467, 20 min). The supernatant was removed, and the fluorescent intensities were measured in the supernatant by using a fluorescence

lization of antibodies onto the polymer surface. This approach is often exploited in dendritic cell (DC)-based immunizations. DCs are of particular interest for vaccines, due to their ability to induce vigorous antigen specific cellular immunity.15,16 Commonly targeted DC receptors10 include CD205 (DEC205),17 CD209 (DC-Sign),18 and CD40.19 Importantly, receptor-mediated targeting not only enhances uptake but is also capable to induce activation of cells, for example, in CD40mediated phagocytosis. Targeting antigens in conjunction with activation of professional antigen presenting cells are key requisites necessary for the induction of protective and therapeutic cellular immunity.16 This is in particular challenging in the setting of infectious liver diseases, since the liver is prone to induce tolerance.20 The latter contributes to the fact that the liver is the target and host of various pathogens such as hepatitis B/C, cytomegalovirus, and malaria for which effective preventive or therapeutic vaccines have been difficult to develop.21 The aim of the present study was to evaluate the uptake behavior of biodegradable microcapsules (MC) functionalized with two different antibodies, anti-CD40 and anti-DEC205, targeting receptors on macrophages and dendritic cells, by nonparenchymal liver cells (NPCs). In addition, microcapsules were equipped with monophosphoryl lipid A (MPLA), a synthetic toll-like-receptor 4 (TLR4) agonist, with the intention to mature the dendritic cell fraction within the NPC population. During the course of this investigation, two main observations were made: first, microcapsules synthesized from hydroxyethyl starch (HES) ended up primarily in the liver, while mannose particles displayed a lung preference; second, MPLA coating not only induced maturation of liver dendritic cells, but in addition resulted in accelerated uptake in vitro and in vivo by Kupffer cells and liver DCs, representing a major fraction within liver NPCs. To our knowledge, the herein presented experimental approach for the first time documents the ability of MPLA, a broadly applied vaccine adjuvant, to serve not only as an immune modulator but also as a targeting compound.

2. MATERIALS AND METHODS 2.1. Microcapsule Synthesis. 2.1.1. Materials Used for Synthesis of Microcapsules. Materials purchased included hydroxyethyl starch (HES, Mw = 200 000 g·mol−1 (Fresenius Kabi), mannose, 2,4toluene diisocyanate (TDI) and cyclohexane (>99.9%) (SigmaAldrich), sodium dodecyl sulfate (SDS) (Fluka), N-ethyl-N′-(3(dimethylamino)propyl)-carbodiimide (EDC), and monochloroacetic acid (MCA) (Aldrich). The oil-soluble surfactant poly((ethylene-cobutylene)-b-(ethylene oxide)), P(E/B-b-EO), was synthesized under anionic polymerization conditions at the Max Planck Institute (MPI).22 Cy5-labeled oligonucleotides (5′-Cy5-CCACTCCTTTCCAGAAAACT-3′) were synthesized by Thermo Scientific (Germany). IRDye 800CW infrared dye was obtained from LI-COR. 4Sulfotetrafluorophenyl (STP) was synthesized at the MPI.23 2.1.2. Preparation of Microcapsules. Microcapsules (MCs) were prepared by a polyaddition reaction applying the inverse miniemulsion procedure.24−26 Briefly, 1400 mg of an aqueous HES (100 mg·mL−1) solution or 100 mg of mannose solved in 1300 mg of PBS buffer were mixed with the Cy5-labeled oligonucleotides (100 pmol·μL−1) (mixture I). Then 100 mg of the surfactant P(E/B-b-EO) was dissolved in 7.5 g of cyclohexane and added to mixture I and stirred over 1 h at 25 °C. After the homogenization step using a Branson Sonifier W-450-Digital apparatus and a 1/2″ tip under ice cooling, a clear solution consisting of 5 g of cyclohexane, 30 mg of P(E/B-b-EO), 2379

dx.doi.org/10.1021/bm5006728 | Biomacromolecules 2014, 15, 2378−2388

Biomacromolecules

Article

Figure 1. Synthesis of microcapsules (MCs). (A) Scheme of MCs preparation, (B) antibody coupling, and MPLA adsorption. (C) Morphological characterization of HES-cy5-MCs by SEM. (D) Amount of fluorescent dye SR101 released from the MCs after incubation for 24 h at 37 °C in different biological media. spectrometer (microplate reader, Infinite M1000, Tecan, Switzerland). The fluorescent dye SR101 absorbs light at 580 nm and emits light at 605 nm. For the data normalization, a total amount of 1 × 1012 MCs/ mL (solid content 10 mg·mL−1) was used for each experiment. The fluorescence signal was normalized to microcapsules per milliliter at each point of measurement. For each sample, the release of fluorescent dye was calculated from three single measurements and the entire experiment was repeated two times. The measurements of colloidal stability were performed with DLS by keeping the weight to weight capsule to protein ratio similar to the ratio in the performed in vivo experiments. For analysis, the method of Rausch et al. was applied.29 Briefly, the autocorrelation function of the serum capsule mixture is fitted by a sum of the correlation functions of the respective solutions (serum/capsule). During the fitting process, all parameters of the components are kept fixed and the only fitting parameters are the intensity contributions of the serum and capsule in the serum capsule mixture. 2.2. Biological Analysis. 2.2.1. Mice. Female C57BL/6J mice of 5−6 weeks of age were obtained from the Zentrale Versuchstiereinrichtung Mainz, Germany and kept under a 12 h dark, 12 h light cycle (with food and water supply at every time) in the animal facility of the University Hospital, Mainz. The animals were treated in accordance with NIH publications entitled “Principles for Use of Animals” and “Guide for the Care and Use of Laboratory Animals”. All protocols were approved by the local Animal Care and Use Committee (“Landesuntersuchungsamt Rheinland-Pfalz”). 2.2.2. Antibodies. The murine DEC205-antibody was generated in vivo through intraperitoneal injection of the hybridoma cell line NLDC-145/ATCC HB-290 (ATCC) in pristine conditioned nude mice and subsequently purified from the generated ascites. Murine anti-CD40 was purified from the supernate of the hybridoma cell line. Polyclonal murine IgG was purchased from Sigma. 2.2.3. Expansion of the Liver Dendritic Cell Population by Hydrodynamic Gene Delivery of a Human Fms-like Tyrosine Kinase 3 Ligand (hFlT3L) Expressing Plasmid. The cytokine human Fms-like

tyrosine kinase 3 ligand (hFlt3L) mobilizes DCs from bone marrow and can be used to enrich DCs in the liver, enhancing the feasibility of liver DC studies.30 Liver DCs were expanded in vivo through hydrodynamic gene delivery of the plasmid pUMVC3-hFLex expressing the secreted portion of hFlt3L.31 Briefly, 10 μg of pUMVC3-hFLex was dissolved in 2 mL of 0.9% NaCl solution and injected into the tail vein of female C57BL/6J mice within 5 s. The injection was repeated on day 6, the liver was dissected on day 12, and the NPC population isolated as described in 2.2.5. 2.2.4. In Vivo Imaging of Microcapsules. In vivo fluorescence imaging of infrared (IR) labeled HES and mannose MCs was performed with the IVIS Spectrum Imaging system (Caliper Life Sciences). The fluorescence source and filters were set for IR-emitting, with excitation at 745 nm and emission at 800 nm, enabling the visualization of IR-MCs in different organs of C57BL/6J mice. Respectively, 1 mg·mL−1 MCs in 300 μL of 0.9% NaCl solution was injected through the tail vein into untreated and hFlt3L-treated 8-week old mice. C57BL/6J mice injected with 300 μL of 0.9% NaCl solution without MCs served as negative control. To rule out that free (nonencapsulated) IR-dye, for example, due to microcapsule instability, is responsible for the observed organ specific fluorescence signals, different doses (0.015/0.15/1.5/15.0 μg) of free IR dye were injected as control. Importantly, 0.15 μg of IR-dye correlates with the amount of dye administered via IR-MCs outlined above. At 4 h after injection, mice were anesthetized with isoflurane, sacrificed by cervical dislocation, and dissected to isolate organs. Liver, spleen, lungs, brain, and kidneys were transferred immediately after dissection into the image chamber, and acquisition of the image was performed with an integration time of 3 s. 2.2.5. Isolation of Liver Nonparenchymal Cells (NPCs). The nonparenchymal liver cell (NPC) population was isolated and purified after perfusion of the liver of female C57BL/6J mice with collagenase using methods previously described.32 In brief, mice were anesthetized with Ketamine/Rompun, the portal vein was cannulated, and the liver perfused with 20 mL of perfusion medium consisting of HBSS (Ca2+2380

dx.doi.org/10.1021/bm5006728 | Biomacromolecules 2014, 15, 2378−2388

Biomacromolecules

Article

and Mg2+-free, PAN Biotech), 100 U/mL collagenase (Sigma-Aldrich), 0.001% DNase (AppliChem), and 5% heat inactivated fetal calf serum (FCS). This common practice eliminates cells circulating through the liver and not bound firmly to the tissue. The perfused liver was dissected, teased apart, and incubated for 15 min at 37 °C. Incubated liver sections were passed through a 70 μm nylon cell strainer. The collected cell suspension was centrifuged at 300g for 15 min, and the resulting pellet, containing the parenchymal cells (hepatocytes), was discarded. The NPCs remaining in suspension were purified through centrifugation in a 30% Histodenz-HBSS gradient as previously outlined in detail.33 The recovered NPC population was >95% viable, was free of hepatocyte contamination, and was subsequently cultured in medium composed of RPMI 1640, 10% FCS, 1% penicillin/ streptomycin, 1 mM L-glutamine, 1% essential and nonessential amino acids, and 50 μM 2-mercaptoethanol. 2.2.6. In Vitro and in Vivo Loading of NPCs with Microcapsules and Flow Cytometric Analysis. In vitro loading and phenotypic characterization was initiated through coculturing of a NPC cell suspension (106cells·mL−1) for 4 h with 10 μg·mL−1 of Cy5-labled microcapsules (Cy5-MCs) formulations as depicted below. The in vivo uptake of Cy5-MCs within the NPC population was characterized following intravenous (IV) injection (tail vein of C57BL/6J mice) of 300 μL of 0.9% NaCl solution containing Cy5-MCs in a concentration of 1 mg·mL−1. Quantification of MC uptake and phenotype determination were performed by flow cytometry using methods previously described.34 Antibodies used for NPC phenotyping included CD45 (clone 30-F11), CD205 (clone NLDC-145), CD40 (clone 1C10), CD11c (clone N418), CD11b (clone M1/70), F4/80 (clone BM8), and CD31 (clone 390). Samples were acquired on a multichannel cytometer BD LSR II (BD Bioscience) equipped with FACS Diva software (BD Bioscience), followed by analyses with FlowJo 7.6.5. 2.2.7. Analysis of Microcapsule Toxicity. Cell toxicity after MC uptake was determined using the fluorescent dye propidium iodide (PI, BD Pharmingen). NPCs (106 cells·mL−1) were incubated for 4 h with 10 μg·mL−1 MCs and stained for 5 min with 10 μL of PI in the dark according to the manufacturer’s instructions. The percentage of apoptotic cells was measured by flow cytometry. 2.2.8. Cytokine Analysis. Cytokine secretion by NPCs was determined with commercial ELISA kits according to the protocols provided by the supplier (eBioscience). NPCs were loaded in vitro and in vivo as described above (2.2.6) and subsequently cultured for 24− 48 h in a 96-well, flat-bottom plate at 37 °C. Supernatants were harvested and analyzed for the expression of TNF-α, IL-6, IL-12p70, and IFN-γ. 2.2.9. Statistical Analysis. Experiments were performed in triplicate and analyzed using SigmaPlot 11.0.Ink Software. For the comparison of many groups with each other, a one-way ANOVA test was performed. To determine which groups differed significantly, a HolmSidak test (P < 0.001) or a Student−Newman−Keuls test (P < 0.05) was applied.

mide (NHS) or sulfo-NHS (S-NHS) to increase coupling efficiency or create a stable amine-reactive product. The resulting amide link is chemically stable, allowing the longterm use of linked compounds. Unfortunately, NHS and SNHS are prone to fast hydrolyses and are only reactive for a short time period (